Australia bans the use of Ivermectin for Covid-19 patients

Australia prohibit doctors and medical personnel from prescribing Ivermectin for treatment Covid-19. This is in line with the increasing use of these anti-parasitic drugs to treat corona patients.

The Australian Drug Regulator (TGA) said it did not yet know whether Ivermectin was effective and safe in the treatment of Covid-19 patients. While the use of this drug has increased three to four times in recent months.

“Ivermectin is not allowed to be used in Covid-19 (patients) in Australia or other developed countries,” the TGA said. The Guardian, Sunday (12/9).

The TGA is concerned that the public can now take Ivermectin in unsafe doses. Moreover, this drug has a number of serious side effects if consumed in excess of the dose.

“Higher doses may be associated with side effects including severe nausea, vomiting, dizziness, and neurological effects such as dizziness, seizures, and coma,” the TGA said. However, infectious disease doctors, dermatologists, and gastroenterologists can still give this drug to patients with certain diseases.

Last week, Westmead Hospital in Sydney reported an overdose of Ivermectin and other Covid-19 mixtures. However, the TGA detected a 10-fold increase in people wanting to import the drug.

This drug is quite popular anti-vaccination community and the right wing. Even before the ban, the off-label Ivermectin recipe was quietly discussed in digital communities on Facebook and Telegram.

President of the Royal Australian College of General Practitioners Dr Karen Price urged patients to ignore this drug recommendation for Covid-19. “Get the vaccine right away and tell friends and family to do the same,” Price said.

See also  Bukele against the Sala: "If I were a dictator, I would have shot them all. You save a thousand lives in exchange for five" | News from El Salvador

Previously, the Head of the Food and Drug Administration (BPOM) Penny K. Lukito gave approval for the Clinical Trial (PPUK) of Ivermectin as a Covid-19 drug. Penny said that the approval for this approval was due to the support of analysis from several clinical trial results using the randomized control trial methodology.

“Thus, public access to drugs (Covid-19) can be carried out immediately widely in clinical trials,” said Penny at a press conference at her office, Jakarta, Monday (28/6).


Leave a Comment